Sam Ononge
ID: UNCST-2020-R000328
|
A CLINICAL TRIAL TO EVALUATE THE PERFORMANCE AND SAFETY OFTHE WEKEBERE SYSTEM FOR MONITORING FETAL WELLBEING DURING LABOUR
REFNo: HS3407ES
The overall objective of this study is to demonstrate safety and performance of wekebere fetal monitoring system.
Specific Objectives
To determine accuracy of wekebere fetal monitoring in comparison with gold standard. To determine the safety of wekebere system
To determine’ uterine contractions
|
Uganda |
2025-06-30 9:35:11 |
2028-06-30 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Felix Bongomin
ID: UNCST-2020-R014224
|
LIAISON® QuantiFERON®-TB Gold Plus II for the Diagnosis of Active and Latent Tuberculosis in Uganda
REFNo: HS6213ES
To evaluate the automated LIAISON® QuantiFERON® -TB Gold plus II immunoassay for the detection of IFN-γ in human lithium heparin plasma from subjects at low risk for M. tuberculosis infection, mixed risk for M. tuberculosis infection and with active TB disease.,
|
Uganda |
2025-06-30 9:16:34 |
2028-06-30 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Haruna Muwonge
ID: UNCST-2019-R000128
|
Retrospective Analysis of RSV RTI Prevalence, Coinfections, and Risk Factors among Older Adults in Uganda: A Study Based on Sentinel Surveillance Data
REFNo: HS5423ES
Objectives
General Objective
To determine the prevalence, associated factors, and coinfection patterns of Respiratory Syncytial Virus (RSV) respiratory tract infections (RTI) among adults aged 60 and above in Uganda using sentinel surveillance data.
Specific Objectives
1. To determine the prevalence and seasonal trends of RSV RTI among older adults in Uganda using data collected from sentinel surveillance sites
2. To examine the relationship between comorbid conditions such as cardiovascular disease, diabetes, and chronic kidney disease, and the severity of RSV RTI among older adults in Uganda.
3. To determine the prevalence of coinfections with other respiratory viruses—SARS-CoV-2, Influenza A/B, and Pandemic A(H1N1) 2009—among older adults with RSV RTIs in Uganda.
4. To assess the association between coinfections with other respiratory viruses —SARS-CoV-2, Influenza A/B, and Pandemic A(H1N1) 2009— and clinical outcomes, including disease severity, hospitalization rates, and mortality, among older adults with RSV RTIs in Uganda.
|
Uganda |
2025-06-30 9:14:46 |
2028-06-30 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Peter Elyanu James
ID: UNCST-2021-R013210
|
OPTIMAH Study: OPTImizing Malaria And HIV treatment in a shifting landscape in Africa
REFNo: HS6165ES
PRIMARY OBJECTIVES
1. Assess the impact of HIV/DTG on weight gain (BMI) in Ugandan children ages 5 to 17 years of age over two years of follow-up.
2. Assess for PK drug-drug interactions between the two most widely used ACTs
(AL or AS-AQ) and DTG in longitudinal cohorts of HIV-uninfected children and CLHIV living in a high endemic malaria region (Busia).
3. To assess the 28- and 42-day efficacy of AL and AS-AQ for the treatment of uncomplicated malaria in children with and without HIV in a setting where artemisinin resistance has emerged.
SECONDARY OBJECTIVES
1. To assess the impacts of DTG on changes in body composition, waist circumference, and metabolic derangements over 2-years of longitudinal follow-up.
2. To assess the impact of repeated malaria infection on changes in weight gain in CLHIV on DTG (comparing HIV-infected cohorts in Busia and Kampala).
3. To determine if changes in DTG PK exposure in the presence of repeated courses of ACTs are associated with impacts on virologic control (pharmacodynamics).
4. To assess for the development of dolutegravir-associated resistance mutations over two years of follow-up.
5. To determine if changes in ACT exposure in the presence of daily DTG for HIV treatment are associated with impacts on malaria treatment outcomes.
6. To critically compare the PK exposure of artemether, artesunate, and DHA in the context of the two leading ACTs in Africa and assess for associations between the PK exposure of artemisinin derivatives as drivers of parasitologic outcomes such as parasite clearance rates for artemisinin-sensitive and resistant infections.
7. To assess levels of gametocytemia in children with and without HIV infection and with artemisinin-sensitive and -resistant infections
8. To determine if repeated course of AL and AS-AQ are associated with selection of resistance-associated mutations to the partner drugs and/or the artemisinin component.
9. To identify novel mutations in known and/or putative loci associated with resistance to artemisinins, lumefantrine, and amodiaquine using amplicon-based sequencing and/or other genotyping methods.
10. To assess the exposure of unbound DTG, lumefantrine, and DEAQ and association with clinical outcomes (viral load or parasitemia)
|
Uganda |
2025-06-26 23:59:42 |
2028-06-26 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Daniel Magumba
ID: UNCST-2025-R018334
|
PEDESTRIAN ROAD SAFETY IN KAMPALA: A MIXED METHODS STUDY OF THE WALKABILITY OF KAMPALA’S ROAD INFRASTRUCTURE
REFNo: HS6064ES
1.To assess the Walkability of Kampala City’s Road infrastructure.
2.To explore stakeholder perceptions on pedestrian safety and walkability of Kampala city.
|
Uganda |
2025-06-26 23:54:31 |
2028-06-26 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|